<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2000
ENTREMED, INC.
(Exact name of issuer as specified in charter)
<TABLE>
<S> <C> <C>
Delaware 0-20713 58-1959440
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer Identification
incorporation Number)
</TABLE>
9640 Medical Center Drive
Rockville, Maryland
-------------------
(Address of principal executive offices)
20850
-----
(Zip code)
(301) 217-9858
--------------
(Registrant's telephone number, including area code)
<PAGE> 2
Item 5. Other Events
Filed herewith as Exhibits 99.1 and 99.2 are copies of press
releases issued by EntreMed, Inc. (the "Company") on June 2, 2000 and June 6,
2000, respectively. Such press releases are incorporated herein by reference.
In reference to the press release incorporated herein as Exhibit
99.1, on June 8th, 2000, the Company was served with legal documents from Abbott
Laboratories, an Illinois corporation, as a defendant in a lawsuit over
inventorship and rights to the antiangiogenic properties of the kringle 5
molecule. Also named as defendants in the lawsuit were Children's Medical Center
in Boston, Dr. Judah Folkman, Dr. Michael O'Reily and Dr. Yihai Cao.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
The exhibits listed in the Exhibit Index are filed herewith.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
EntreMed, Inc. has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ENTREMED, INC.
(Registrant)
/s/ R. NELSON CAMPBELL
------------------------------
R. Nelson Campbell
Chief Financial Officer
Date: June 12, 2000
EXHIBIT INDEX
Exhibit No. Description
99.1 Text of Press Release, dated June 2, 2000.
99.2 Text of Press Release, dated June 6, 2000.
3
